Skip to Content
Merck
CN
All Photos(1)

Documents

P7306

Sigma-Aldrich

Polyethylene glycol/ dimethyl sulfoxide solution

Hybri-Max, average mol wt 1,450, 50 % (w/v), 0.2 μm filtered, BioReagent, suitable for hybridoma

Synonym(s):

PEG/DMSO Solution, Polyethylene Glycol Solution, Solution of PEG and DMSO

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12161902
PubChem Substance ID:
NACRES:
NA.75

grade

Hybri-Max

Quality Level

sterility

0.2 μm filtered

product line

BioReagent

form

solution

mol wt

average mol wt 1,450

concentration

50 % (w/v)

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

storage temp.

2-8°C

SMILES string

C(CO)O

InChI

1S/C2H6O2/c3-1-2-4/h3-4H,1-2H2

InChI key

LYCAIKOWRPUZTN-UHFFFAOYSA-N

Application

PEG is used as a fusogen to obtain hybridomas for monoclonal antibody production. Induces cell hybridization.


Recommended for use in a normal fusion protocol requiring 50% PEG and 10% DMSO.

Packaging

Packaged in sealed ampules under nitrogen.

Other Notes

Contains 50% (w/v) polyethylene glycol (Av. Mol. Wt. 1450) and 10% DMSO (v/v) in DPBS without Calcium.

Reconstitution

Solution is ready-to-use. If a less concentrated solution is desired, dilute with sterile DPBS without calcium (D5773). Some precipitate may appear after being exposed to cooler, but should disappear as the solution warms. Solution may be frozen if desired but should first be aliquotted to avoid repeated freeze/thaw cycles.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wen-Hung Chen et al.
Virology journal, 14(1), 189-189 (2017-10-04)
Dengue virus (DV) infection causes a spectrum of clinical diseases ranging from dengue fever to a life-threatening dengue hemorrhagic fever. Four distinct serotypes (DV1-4), which have similar genome sequences and envelope protein (E protein) antigenic properties, were divided. Among these
Indre Kucinskaite-Kodze et al.
Biomolecules, 10(7) (2020-07-12)
The pathogenicity of many bacteria, including Streptococcus pneumoniae, depends on pore-forming toxins (PFTs) that cause host cell lysis by forming large pores in cholesterol-containing cell membranes. Therefore, PFTs-neutralising antibodies may provide useful tools for reducing S. pneumoniae pathogenic effects. This
Shudan Wang et al.
Theranostics, 10(15), 6854-6874 (2020-06-20)
Repeated failures of "Aβ-lowering" therapies call for new targets and therapeutic approaches for Alzheimer's disease (AD). We propose to treat AD by halting neuronal death and repairing synapses using a BDNF-based therapy. To overcome the poor druggability of BDNF, we
Hong Chang et al.
Oncology letters, 22(5), 749-749 (2021-09-21)
The receptor tyrosine kinase, anexelekto (Axl) is involved in tumor cell growth, migration and invasion, and has been associated with chemotherapy resistance, which makes it an attractive target for cancer therapy. In total, six Axl-targeted monoclonal antibodies (mAbs) and two
Liliana R Loureiro et al.
Scientific reports, 8(1), 12196-12196 (2018-08-17)
Incomplete O-glycosylation is a feature associated with malignancy resulting in the expression of truncated glycans such as the sialyl-Tn (STn) antigen. Despite all the progress in the development of potential anti-cancer antibodies, their application is frequently hindered by low specificities

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service